Literature DB >> 30655374

Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia.

Sasan Zandi1,2, Solaf Kanfar3,4, Christine Cserti-Gazdewich1,2,3,4, Jeffrey H Lipton3,4, Jacob Pendergrast5,2,3,4.   

Abstract

Entities:  

Year:  2019        PMID： 30655374      PMCID： PMC6395320          DOI： 10.3324/haematol.2018.203943

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Successful treatment of coeliac disease by allogeneic haematopoietic stem cell transplantation.

Authors:  J Hans Hoekstra; Jacqueline J Groot-Loonen; Annemieke van der Weij; Peter M Hoogerbrugge; Yvonne Kooy; Frits Koning
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-12       Impact factor: 2.839

2.  Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation.

Authors:  R L Rogers; T A Javed; R E Ross; G Virella; R K Stuart; D Frei-Lahr
Journal:  Am J Hematol       Date:  1998-04       Impact factor: 10.047

3.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect.

Authors:  M Mielcarek; W Leisenring; B Torok-Storb; R Storb
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

4.  Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.

Authors:  Frederick Fasslrinner; Johannes Schetelig; Andreas Burchert; Michael Kramer; Rudolf Trenschel; Ute Hegenbart; Michael Stadler; Kerstin Schäfer-Eckart; Michael Bätzel; Hans Eich; Martin Stuschke; Rita Engenhart-Cabillic; Mechthild Krause; Peter Dreger; Andreas Neubauer; Gerhard Ehninger; Dietrich Beelen; Wolfgang E Berdel; Timo Siepmann; Matthias Stelljes; Martin Bornhäuser
Journal:  Lancet Haematol       Date:  2018-03-14       Impact factor: 18.959

Review 5.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

6.  The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Authors:  James A Russell; William Irish; Alexander Balogh; M Ahsan Chaudhry; Mary Lynn Savoie; A Robert Turner; Loree Larratt; Jan Storek; Nizar J Bahlis; Christopher B Brown; Diana Quinlan; Michelle Geddes; Nancy Zacarias; Andrew Daly; Peter Duggan; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-03       Impact factor: 5.742

7.  Correction of celiac disease after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia.

Authors:  Ronald M Kline; Steven M L Neudorf; Howard I Baron
Journal:  Pediatrics       Date:  2007-09-24       Impact factor: 7.124

Review 8.  Advances in the allogeneic transplantation for thalassemia.

Authors:  Guido Lucarelli; Javid Gaziev
Journal:  Blood Rev       Date:  2007-11-26       Impact factor: 8.250

Review 9.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

10.  Transfer of IgA deficiency to a bone-marrow-grafted patient with aplastic anaemia.

Authors:  L Hammarström; B Lönnqvist; O Ringdén; C I Smith; T Wiebe
Journal:  Lancet       Date:  1985-04-06       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.